Healthcare leaders find themselves dismayed after the latest government spending bill, signed by President Joe Biden, omitted several critical healthcare provisions. While the president’s move averted a government shutdown, it left out essential reforms like drug pricing and prior authorization. The original bill, which contained these provisions, encountered opposition from figures such as Tesla CEO Elon Musk and President-elect Donald Trump, who considered it to include unnecessary expenditure, as reported by The Washington Post.
Key reforms, according to advocacy group Patients for Affordable Drugs Now, fell victim to political maneuvering and were omitted from the revised package. These reforms included the Affordable Prescriptions for Patients Act, which aimed to cap patents on biologics, and the Modernizing and Ensuring PBM Accountability Act, designed to sever the link between pharmacy benefit managers’ (PBM) earnings and drug costs in Medicare Part D. These initiatives had previously received bipartisan support, promised taxpayer savings, and targeted relief for patients. Merith Basey, the executive director of Patients for Affordable Drugs Now, remarked that politics and external influences took precedence over patient needs, leaving Americans paying some of the highest drug prices globally.
The exclusion extends beyond drug pricing, as reforms to prior authorization processes and solutions for declining Medicare reimbursement rates were also neglected. The American Medical Association condemned these omissions, highlighting a 2.83% cut for doctors and the lack of any rational, inflation-adjusted update that was recommended by the Medicare Payment Advisory Commission.
Furthermore, the spending bill only provided brief extensions for Medicare telehealth flexibilities and the Acute Hospital Care at Home program, extending both until March 31, 2025. These were significantly shorter than the prior bill’s longer-term solutions. Kyle Zebley from the American Telemedicine Association viewed the outcome as less than ideal but acknowledged it as a step towards maintaining telehealth access without disruption, as stated in a statement made by the organization.
The absence of these key provisions delays potential relief for millions of Americans, deferring any possibility of their ratification to a future session of Congress. The healthcare community remains unsettled as the political landscape continues to overshadow the pressing needs for reform.